Coya Therapeutics IncNASDAQ:COYA
- LAST PRICE4.6100
- TODAY'S CHANGE (%)0.2700 (6.2212%)
- Bid / Lots4.6000/ 5
- Ask / Lots4.7500/ 5
- Open / Previous Close4.5900 / 4.3400
- Day Range
- 52 Week Range
- Volume367,540
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COYA |
|---|---|---|
| 09:32 ET | 9970 | 4.67 |
| 09:34 ET | 15950 | 4.51 |
| 09:36 ET | 25393 | 4.5 |
| 09:38 ET | 6825 | 4.54 |
| 09:39 ET | 4470 | 4.54 |
| 09:41 ET | 750 | 4.62 |
| 09:43 ET | 2250 | 4.6185 |
| 09:45 ET | 3500 | 4.5994 |
| 09:48 ET | 425 | 4.5982 |
| 09:50 ET | 4995 | 4.67 |
| 09:52 ET | 1309 | 4.75 |
| 09:54 ET | 670 | 4.62 |
| 09:56 ET | 544 | 4.6381 |
| 09:57 ET | 300 | 4.6056 |
| 09:59 ET | 7150 | 4.75 |
| 10:01 ET | 4076 | 4.76 |
| 10:03 ET | 500 | 4.715 |
| 10:06 ET | 4743 | 4.77 |
| 10:08 ET | 1207 | 4.8 |
| 10:10 ET | 1210 | 4.7999 |
| 10:19 ET | 6846 | 4.6 |
| 10:21 ET | 240 | 4.6219 |
| 10:24 ET | 200 | 4.6 |
| 10:26 ET | 4914 | 4.525 |
| 10:28 ET | 8788 | 4.53 |
| 10:30 ET | 4102 | 4.51 |
| 10:32 ET | 600 | 4.56 |
| 10:33 ET | 250 | 4.5999 |
| 10:37 ET | 741 | 4.5024 |
| 10:39 ET | 843 | 4.5286 |
| 10:42 ET | 2850 | 4.5475 |
| 10:44 ET | 300 | 4.55 |
| 10:46 ET | 1178 | 4.55 |
| 10:48 ET | 1187 | 4.55 |
| 10:50 ET | 800 | 4.5001 |
| 10:51 ET | 100 | 4.54 |
| 10:55 ET | 719 | 4.57 |
| 10:57 ET | 1000 | 4.5784 |
| 11:00 ET | 4428 | 4.6839 |
| 11:02 ET | 1000 | 4.6899 |
| 11:04 ET | 1700 | 4.6 |
| 11:09 ET | 100 | 4.61 |
| 11:13 ET | 5200 | 4.62 |
| 11:15 ET | 100 | 4.62 |
| 11:18 ET | 300 | 4.62 |
| 11:20 ET | 9323 | 4.75 |
| 11:22 ET | 6783 | 4.59 |
| 11:24 ET | 600 | 4.675 |
| 11:27 ET | 100 | 4.63 |
| 11:29 ET | 651 | 4.6 |
| 11:33 ET | 600 | 4.595 |
| 11:36 ET | 900 | 4.635 |
| 11:38 ET | 200 | 4.6 |
| 11:40 ET | 1200 | 4.698 |
| 11:42 ET | 400 | 4.64 |
| 11:44 ET | 200 | 4.65 |
| 11:45 ET | 1900 | 4.68 |
| 11:47 ET | 300 | 4.65 |
| 11:49 ET | 800 | 4.65 |
| 11:51 ET | 300 | 4.675 |
| 11:54 ET | 1250 | 4.65 |
| 11:56 ET | 1400 | 4.6 |
| 11:58 ET | 400 | 4.6 |
| 12:00 ET | 440 | 4.6 |
| 12:02 ET | 300 | 4.6 |
| 12:03 ET | 300 | 4.6 |
| 12:05 ET | 300 | 4.6 |
| 12:07 ET | 200 | 4.6 |
| 12:09 ET | 300 | 4.6 |
| 12:12 ET | 900 | 4.615 |
| 12:14 ET | 1000 | 4.58 |
| 12:21 ET | 200 | 4.595 |
| 12:23 ET | 4000 | 4.51 |
| 12:25 ET | 1083 | 4.525 |
| 12:30 ET | 100 | 4.53 |
| 12:34 ET | 3719 | 4.58 |
| 12:36 ET | 100 | 4.575 |
| 12:39 ET | 100 | 4.595 |
| 12:43 ET | 200 | 4.595 |
| 12:45 ET | 100 | 4.595 |
| 12:48 ET | 100 | 4.64 |
| 12:50 ET | 200 | 4.595 |
| 12:52 ET | 250 | 4.6316 |
| 12:59 ET | 100 | 4.59 |
| 01:06 ET | 2500 | 4.57 |
| 01:08 ET | 2600 | 4.57 |
| 01:14 ET | 700 | 4.585 |
| 01:15 ET | 602 | 4.585 |
| 01:17 ET | 300 | 4.6 |
| 01:19 ET | 200 | 4.6 |
| 01:21 ET | 510 | 4.6 |
| 01:24 ET | 200 | 4.6 |
| 01:32 ET | 200 | 4.6 |
| 01:39 ET | 218 | 4.575 |
| 01:46 ET | 100 | 4.575 |
| 01:48 ET | 1091 | 4.5501 |
| 01:50 ET | 539 | 4.57 |
| 01:51 ET | 602 | 4.5308 |
| 02:06 ET | 700 | 4.5435 |
| 02:08 ET | 6550 | 4.58 |
| 02:09 ET | 474 | 4.6 |
| 02:11 ET | 200 | 4.605 |
| 02:15 ET | 4531 | 4.67 |
| 02:18 ET | 100 | 4.655 |
| 02:20 ET | 200 | 4.74 |
| 02:22 ET | 425 | 4.74 |
| 02:24 ET | 2200 | 4.74 |
| 02:26 ET | 200 | 4.75 |
| 02:38 ET | 100 | 4.73 |
| 02:40 ET | 1837 | 4.738 |
| 02:44 ET | 200 | 4.61 |
| 02:45 ET | 389 | 4.61 |
Today
Sector Update: Health Care Stocks Falling Wednesday Afternoon, from 51 minutes ago by MT Newswires
51 minutes ago by MT NewswiresCoya Therapeutics Says Alzheimer's Disease Treatment Showed 'Significant Improvement' in Cognitive Function, from 5 hours ago by MT Newswires
5 hours ago by MT NewswiresCoya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD), from 8 hours ago by Business Wire
8 hours ago by Business Wire
Jun 5, 2023
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothee, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer's Disease (AD), from 7:00AM ET on Monday Jun 05, 2023 by Business Wire
7:00AM ET on Monday Jun 05, 2023 by Business Wire
May 23, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Coya Therapeutics Inc | 43.2M | -3.4x | --- |
Magenta Therapeutics Inc | 43.4M | -0.5x | --- |
Eledon Pharmaceuticals Inc | 43.4M | -0.3x | --- |
Atreca Inc | 42.7M | -0.5x | --- |
Sensei Biotherapeutics Inc | 43.8M | -0.9x | --- |
Corbus Pharmaceuticals Holdings Inc | 41.7M | -0.8x | --- |
Company Information
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on the development of medicinal products to modulate the function of regulatory T cells (Tregs). Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. Its 300 Series product candidates include COYA 301 and COYA 302. Its 200 Series product candidates include COYA 201 and COYA 206. Its 100 Series product candidate is COYA 101.
Contact Information
- Headquarters
- 5850 San Felipe St., Suite 500HOUSTON, TX, United States 77057
- Phone
- 650-739-3939
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Howard Berman
- President, Chief Medical Officer
- Adrian Hepner
- Chief Financial Officer, Chief Operating Officer
- David Snyder
- Independent Director
- Hideki Garren
- Independent Director
- Dov Goldstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $43.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 9.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.34 |
Book Value | $-0.84 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
